Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

The US overweight and obese population will rise significantly in the next quarter century if current trends continue, and ...

They’re used to treat type 2 diabetes and obesity.These drugs curb the cravings for high-calorie foods, helping users eat ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...

Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

In fact, more and more teens that meet certain weight and health criteria are going on GLP-1s after the FDA’s approval of ...

Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world’s first-ever fluorescently tagged ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.